Pharma and Biosimilar Litigation in Canada - Navigating the PM (NOC) Regulations

  • October 05, 2016

PURCHASE

Publication Only | Archived Video + e-Materials

DESCRIPTION

Hear from experienced litigators from both the generic and brand sides as well as in-house counsel and the Bench on best practices for litigating under the Patented Medicines (Notice of Compliance) Regulations. Our expert faculty will assist you to conduct proceedings under the Regulations efficiently and in a cost-effective manner, and will provide valuable insights on the current state of pharmaceutical and biosimilar litigation in Canada.

PROGRAM CHAIRS

Geoff Mowatt, Dimock Stratton LLP
Vincent de Grandpré, Osler Hoskin Harcourt LLP

TABLE OF CONTENTS

Meeting Counsel Expectations PowerPoint Slides
David Blais, Mylan Pharmaceuticals ULC
Denise Lacombe, AstraZeneca Canada Inc.

Framing a Winning Notice of Allegation PowerPoint Slides
Dino Clarizio, Goodmans LLP
David Reive, Miller Thomson LLP

Getting a Strategic Advantage: Court Filings and Interlocutory Matters
Fiona Legere, McCarthy Tétrault LLP 
Kavita Ramamoorthy, Deeth Williams Wall LLP

Getting a Strategic Advantage: Court Filings and Interlocutory Matters PowerPoint Slides
Fiona Legere, McCarthy Tétrault LLP 
Kavita Ramamoorthy, Deeth Williams Wall LLP

Lessons from Recent Experimental Testing Cases
Jordana Sanft, Norton Rose Fulbright Canada LLP 
Sana Halwani, Gilbert's LLP

Building the Foundation of Your Case PowerPoint Slides
Jordana Sanft, Norton Rose Fulbright Canada LLP 
Sana Halwani, Gilbert's LLP

The Art (But Mostly Science) Of Cross-Examination in PM(NOC) Proceedings 
Dominique Hussey, Bennett Jones LLP
Mark Davis, Belmore Neidrauer LLP

Imagining Litigation Under Better Regulations
Nathaniel Lipkus, Osler, Hoskin & Harcourt LLP
Andrew Bernstein, Torys LLP

Preparing for and Conducting a Successful Hearing PowerPoint Slides
Scott Beeser, Aitken Klee LLP
Christopher Van Barr, Gowling WLG